Lung cancer is one of the leading causes of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about ...

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response ...

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body’s immune response ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

particularly non-small cell lung cancer (NSCLC) and pancreatic cancer, according to results from a phase II study. Among 158 evaluable patients with 10 tumor types, 30% had an overall response ...

Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's ...

Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

Researchers have discovered a particular type of cancer cell that relies on its own biological electric utility company to thrive. Disrupting this power plant – with the help of a puffer fish – showed ...

Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their own electric network, like that seen in the body's nervous system.

Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...